AUS
NZ
UK
CA
USA
IND
Highlights:
- FDA Fast Track Status: Clarity Pharmaceuticals has received fast track status from the US FDA for its prostate cancer imaging compound, 64Cu-SAR-bisPSMA, which is designed for PET scans.
- Accelerated Approval: The fast track designation aims to expedite the regulatory process, potentially leading to quicker commercialization if the compound demonstrates superior imaging performance.
- Ongoing Trials: Clarity is advancing its clinical trials, including the CLARIFY Phase III trial, and preparing for an End of Phase meeting with the FDA for a second pivotal Phase III trial.
Clarity Pharmaceuticals (ASX:CU6) has announced that the US FDA has granted fast track status to its innovative prostate cancer imaging compound, 64Cu-SAR-bisPSMA, designed for PET scans.
This designation is a significant boost for Clarity's product, which aims to enhance prostate cancer imaging by using a compound that improves visibility on PET scans. The fast track status expedites the regulatory process, potentially leading to a quicker path to commercialization if the compound proves to be effective.
The fast track status allows Clarity to engage more closely with the FDA, facilitating the development and approval process. The company is currently advancing its clinical trials, including the CLARIFY Phase III trial and preparing for an End of Phase meeting with the FDA for a second pivotal Phase III trial.
Dr. Alan Taylor, Clarity’s Executive Chairman, highlighted that this milestone supports the company's efforts to accelerate the approval of 64Cu-SAR-bisPSMA, marking an important step forward in its quest to offer a superior diagnostic tool for prostate cancer.
